In this issue of Cardiovascular Revascularization Medicine, Giacaman et al. present 12 month results of a non-randomized, multi-center registry (ROSES) designed to assess safety and effectiveness of the Orsiro bio-resorbable polymer sirolimus-eluting stent (BPSES) among a non-selected population treated in Chile . The rationale for the study was two-fold: (1) to assess outcomes among a higher risk population than reported from randomized clinical trials and (2) to assess outcomes in a Latin American population that has been underrepresented in clinical trials. The specific population in this analysis is of interest given the high prevalence of diabetes (40%) and advanced disease at presentation.